Jennii Luu
Papers
2
Total Citations
80
H-Index
2
About
Jennii Luu is a translational cancer researcher whose work bridges the critical gap between preclinical models and effective therapies for hard-to-treat malignancies. Her primary research focuses on developing high-throughput drug screening platforms for rare and understudied cancers, particularly prostate and ovarian malignancies. Luu’s landmark 2021 study, cited 67 times, pioneered a high-throughput imaging assay for drug screening in 3D prostate cancer organoids derived from patient-derived xenografts, directly addressing the scarcity of preclinical models for advanced prostate cancer. Her 2024 work, already garnering 13 citations, tackles low-grade serous ovarian carcinoma (LGSOC), a rare epithelial ovarian cancer often excluded from pivotal clinical trials due to insufficient case numbers. By creating robust screening platforms for these neglected tumor types, Luu enables the identification of novel therapeutics where standard approaches fall short. Her contributions are particularly impactful for researchers seeking to translate organoid-based models into actionable drug discovery pipelines. Luu’s work exemplifies how methodical assay development can expand the preclinical landscape for cancers that have historically been underserved by traditional research models.
Research Focus
Key Achievements
Top Papers
- 1
- 2